Active, not recruitingPhase 2NCT05247905
Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors
Studying Neuroendocrine tumor of pancreas
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Alliance for Clinical Trials in Oncology
- Principal Investigator
- Timothy J. b, MDMayo Clinic
- Intervention
- Lutetium Lu 177 Dotatate(drug)
- Enrollment
- 31 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2033
Study locations (30)
- Fairbanks Memorial Hospital, Fairbanks, Alaska, United States
- Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
- Tower Cancer Research Foundation, Beverly Hills, California, United States
- Epic Care-Dublin, Dublin, California, United States
- Bay Area Breast Surgeons Inc, Emeryville, California, United States
- Epic Care Partners in Cancer Care, Emeryville, California, United States
- Cedars Sinai Medical Center, Los Angeles, California, United States
- Contra Costa Regional Medical Center, Martinez, California, United States
- Bay Area Tumor Institute, Oakland, California, United States
- Torrance Memorial Physician Network - Cancer Care, Torrance, California, United States
- Epic Care Cyberknife Center, Walnut Creek, California, United States
- BASS Medical Group - Lennon, Walnut Creek, California, United States
- Rocky Mountain Cancer Centers-Aurora, Aurora, Colorado, United States
- Boulder Community Foothills Hospital, Boulder, Colorado, United States
- Rocky Mountain Cancer Centers-Boulder, Boulder, Colorado, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05247905 on ClinicalTrials.govOther trials for Neuroendocrine tumor of pancreas
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07273409Pancreatic Neuroendocrine Tumour - Optimal Surgical Debulking or NotUppsala University
- ENROLLING BY INVITATIONPHASE2NCT07121478Patients With High-grade Pancreatic Neuroendocrine TumorsNational Cancer Center, Korea
- RECRUITINGPHASE2, PHASE3NCT06943755Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine TumorsExelixis
- RECRUITINGPHASE1NCT06663072Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine TumorsUniversity of Chicago
- RECRUITINGPHASE1NCT05687123Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine TumorsNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGNCT06406387ATRX/DAXX in EUS-FNB Specimens of Pan-NETsAzienda Ospedaliera Universitaria Integrata Verona
- RECRUITINGNCT06121622Development of New Personalised 3D Preclinical Models of Pancreatic Neuroendocrine TumoursIRCCS San Raffaele
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT06148636A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine TumorsDavid Bushnell